It's absolutely fantastic that we are moving the along phase 3 trial, in fact we are 1/3 finished and more than 1/2 completed for the futility analysis. We also have the renal trial commencing and possibly other indication upcoming. Where management is lacking and is very obvious over the past 12 months is creating shareholder value in the short term, One one really knows whether Rvx has been playing a chess game with potential partners as to getting a large deal with BP done, Whatever happened to the talked about That certified rights deal that protected both parties from trial failure. Upfront money and then ongoing milestone payments upon achieving positive trial results and then buyout upon final drug approval. This seems like the most logical advancement for short term shareholder value. This would also legitimize the science to the world and move things along. I often wonder if we had a change of management in terms of new fresh leader with pharma experience how much faster a deal would get done and how the investor public would now see a great investment. I have rarely been critical of management but now i am feeling very frustrated with the pace of shareholder value. Tell me again why we needed to hire a vp of investor relations ??? Was there really a good reason, maybe that allusive CRD is around the corner and we will now need a vp of investor relations , . I hope something is in the works because nothing else is working to help the share price